EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Evaluation of HER2 status in endometrial carcinoma using endometrial, gastric, and breast cancer criteria: focus on HER2-low

Heesoo Yoon iD, Yeon Bi Han iD, Dong Hoon Suh iD, Kidong Kim iD, Jae Hong No iD, Yong Beom Kim iD, Hyojin Kim iD

Journal of Gynecologic Oncology · 2026 · 37 (5)

DOI: 10.3802/jgo.2026.37.e86 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2026. Verfasst von Heesoo Yoon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Seoul National University College of Medicine Research foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To evaluate human epidermal growth factor receptor 2 (HER2) status in endometrial carcinoma (EC) using 3 different criteria, assess its association with clinicopathological and molecular characteristics, and investigate intertumoral heterogeneity and prognostic significance, focusing on HER2-low. METHODS: HER2 immunohistochemistry was performed on whole-slide sections from 365 EC and interpreted using EC, gastric cancer (GC), and breast cancer (BC) criteria. Silver in situ hybridization was performed for 2+/3+ cases. Intertumoral heterogeneity was assessed in 30 matched primary and recurrent/metastatic tumors. RESULTS: Among 365 ECs, HER2-positive tumors (2.0%) were strongly associated with serous histology, high-grade, and the p53-abnormal (p53-abn) subgroup (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsErb-b2 Receptor Tyrosine KinasesHumansFemaleImmunohistochemistryPrognosisAgedMiddle AgedBiomarkers, TumorTumor Suppressor Protein p53AdultIn Situ HybridizationAged, 80 and overBreast NeoplasmsNeoplasm Recurrence, LocalStomach Neoplasms

Stichwörter der Autor:innen

Biomarkers, TumorEndometrial CarcinomaGenes, erbB-2ImmunohistochemistryPrognosis

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanBiomarkers, TumorTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea.
  • Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.
  • Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea.
  • Department of Pathology, Seoul National University College of Medicine, Seoul, Korea. hyojinkim7137@gmail.com.

ORCID-Profile: Heesoo Yoon, Yeon Bi Han, Dong Hoon Suh, Kidong Kim, Jae Hong No, Yong Beom Kim, Hyojin Kim

Förderung

  • Seoul National University College of Medicine Research foundation

Zitieren

APA

Yoon, H., Han, Y. B., Suh, D. H., Kim, K., No, J. H., Kim, Y. B., & Kim, H. (2026). Evaluation of HER2 status in endometrial carcinoma using endometrial, gastric, and breast cancer criteria: focus on HER2-low. Journal of Gynecologic Oncology, 37(5). https://doi.org/10.3802/jgo.2026.37.e86

Vancouver

Yoon H, Han YB, Suh DH, Kim K, No JH, Kim YB, et al. Evaluation of HER2 status in endometrial carcinoma using endometrial, gastric, and breast cancer criteria: focus on HER2-low. Journal of Gynecologic Oncology. 2026;37(5). doi:10.3802/jgo.2026.37.e86

BibTeX
@article{Yoon2026,
  author = {Yoon, Heesoo and Han, Yeon Bi and Suh, Dong Hoon and Kim, Kidong and No, Jae Hong and Kim, Yong Beom and Kim, Hyojin},
  title = {Evaluation of HER2 status in endometrial carcinoma using endometrial, gastric, and breast cancer criteria: focus on HER2-low},
  journal = {Journal of Gynecologic Oncology},
  year = {2026},
  volume = {37},
  number = {5},
  doi = {10.3802/jgo.2026.37.e86}
}
Kostenlos starten →